ARCA biopharma GAAP EPS of -$0.16
- ARCA biopharma press release (NASDAQ:ABIO): Q3 GAAP EPS of -$0.16.
- Cash and cash equivalents were $43.9 million as of September 30, 2022, compared to $53.4 million as of December 31, 2021.
- ARCA believes that its current cash and cash equivalents, will be sufficient to fund its operations at the current levels through at least the end of 2023.
- The Company’s review of its strategic options may impact this projection.